Development of a method to measure methadone enantiomers and its metabolites without enantiomer standard compounds for the plasma of methadone maintenance patients

Biomedical Chromatography

Volumn 24, Issue 7, 2010, Pages 782-788

  Wang, Sheng Chang ^a   Ho, Ing Kang ^a   Wu, Shiow Ling ^b,c   Liu, Shu Chih ^a   Kuo, Hsiang Wei ^a   Lina, Keh Ming ^a   Liua, Yu Li ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b Graduate Institute of Life Sciences at TKU   (Taiwan)

^c CENTER FOR DISEASE CONTROL   (Taiwan)

Author keywords

CYP2B; CYP2C19; HPLC; R EDDP; R methadone; Racemic; S EDDP; S methadone

Indexed keywords

COLUMN CHROMATOGRAPHY; ENANTIOMERS; LIQUID CHROMATOGRAPHY; PATIENT REHABILITATION; PATIENT TREATMENT; PHASE SEPARATION;

ANALYTICAL COLUMNS; HPLC; PHOTODIODE ARRAYS; PLASMA LEVELS; R-2-ETHYLIDENE-1,5-DIMETHYL-3,3- DIPHENYLPYRROLIDINE; R-METHADONE; RACEMIC; RETENTION TIME; S-2-ETHYLIDENE-1,5-DIMETHYL-3,3- DIPHENYLPYRROLIDINE; S-METHADONE;

METABOLITES;

AMISULPRIDE; BUPRENORPHINE; CARBAMAZEPINE; CITALOPRAM; CLOZAPINE; DEMETHYLCITALOPRAM; DIAZEPAM; DIDEMETHYLCITALOPRAM; DRUG METABOLITE; HALOPERIDOL; IMIPRAMINE; METHADONE; MORPHINE; NORBUPRENORPHINE; NORCLOZAPINE; PAROXETINE; PROTRIPTYLINE; S CITALOPRAM OXYLATE; THIORIDAZINE; UNCLASSIFIED DRUG; VALPROIC ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG STRUCTURE; ENANTIOMER; HUMAN; LIQUID CHROMATOGRAPHY; RACEMIC MIXTURE; SOLID PHASE EXTRACTION;

EID: 77953498774     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1363     Document Type: Article

References (21)

1. Angelo HR, Beck N and Kristensen K. Enantioselective high-performance liquid chromatographic method for the determination of methadone and its main metabolite in urine using an AGP and a C8 column coupled serially. Journal of Chromatography. B, Biomedical Sciences and Applications 1999; 724(1): 35-40.
2. Cao YJ, Smith PF, Wire MB, Lou Y, Lancaster CT, Causon RC, Bigelow GE, Martinez E, Fuchs EJ, Radebaugh C, McCabe S and Hendrix CW. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioiddependent subjects. Pharmacotherapy 2008; 28(7): 863-874.
3. Crettol S, Deglon JJ, Besson J, Croquette-Krokkar M, Gothuey I, Hammig R, Monnat M, Huttemann H, Baumann P and Eap CB. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clinical Pharmacology and Therapeutics 2005; 78(6): 593-604. (Pubitemid 41773635)
4. Eap CB, Buclin T and Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clinical Pharmacokinetics 2002; 41(14): 1153-1193. (Pubitemid 35398691)
5. Etter ML, George S, Graybiel K, Eichhorst J and Lehotay DC. Determination of free and protein-bound methadone and its major metabolite EDDP: enantiomeric separation and quantitation by LC/MS/MS. Clinical Biochemistry 2005; 38(12): 1095-1102. (Pubitemid 41797750)
6. Fernandez P, Lago M, Lorenzo RA, Carro AM, Bermejo AM and Tabernero MJ. Microwave assisted extraction of drugs of abuse from human urine. Journal of Applied Toxicology 2007; 27(4): 373-379. (Pubitemid 47066766)
7. Fucci N and De Giovanni N. Methadone in hair and sweat from patients in long-term maintenance therapy. Therapeutic Drug Monitoring 2007; 29(4): 452-454. (Pubitemid 47220463)
8. Gerber JG, Rhodes RJ and Gal J. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality 2004; 16(1): 36-44. (Pubitemid 37532283)
9. He H, Sun C, Wang XR, Pham-Huy C, Chikhi-Chorfi N, Galons H, Thevenin M, Claude JR and Warnet JM. Solid-phase extraction of methadone enantiomers and benzodiazepines in biological fl uids by two polymeric cartridges for liquid chromatographic analysis. Journal of Chromatography B, Analytical Technologies in the Biomedical and Life Sciences 2005; 814(2): 385-391.
10. Kelly T, Doble P and Dawson M. Chiral analysis of methadone and its major metabolites (EDDP and EMDP) by liquid chromatography-mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2005; 814(2): 315-323.
11. Kintz P, Tracqui A, Marzullo C, Darreye A, Tremeau F, Greth P and Ludes B. Enantioselective analysis of methadone in sweat as monitored by liquid chromatography/ion spray-mass spectrometry. Therapeutic Drug Monitoring 1998; 20(1): 35-40.
12. Kristensen K, Blemmer T, Angelo HR, Christrup LL, Drenck NE, Rasmussen SN and Sjogren P. Stereoselective pharmacokinetics of methadone in chronic pain patients. Therapeutic Drug Monitoring 1996; 18(3): 221-227.
13. Lehotay DC, George S, Etter ML, Graybiel K, Eichhorst JC, Fern B, Wildenboer W, Selby P and Kapur B. Free and bound enantiomers of methadone and its metabolite, EDDP in methadone maintenance treatment: relationship to dosage? Clinical Biochemistry 2005; 38(12): 1088-1094.
14. Mitchell TB, Dyer KR, Newcombe D, Somogyi AA and White JM. Fluctuations in (R,S)-methadone pharmacokinetics and response among long-term methadone maintenance patients. Addiction Biology 2006; 11(2): 170-174.
15. Rodriguez-Rosas ME, Medrano JG, Epstein DH, Moolchan ET, Preston KL and Wainer IW. Determination of total and free concentrations of the enantiomers of methadone and its metabolite (2-ethylidene-1,5-dimethyl- 3,3-diphenyl- pyrrolidine) in human plasma by enantioselective liquid chromatography with mass spectrometric detection. Journal of Chromatography. A 2005; 1073(1-2): 237-248.
16. Rudaz S and Veuthey JL. Chiral stationary phases in HPLC for the stereoselective determination of methadone. Chirality 1999; 11(4): 319-325.
17. Stocker H, Kruse G, Kreckel P, Herzmann C, Arasteh K, Claus J, Jessen H, Cordes C, Hintsche B, Schlote F, Schneider L and Kurowski M. Nevirapine signifi cantly reduces the levels of racemic methadone and (R)-methadone in human immunodefi ciency virus-infected patients. Antimicrobial Agents and Chemotherapy 2004; 48(11): 4148-4153.
18. Totah RA, Sheff els P, Roberts T, Whittington D, Thummel K and Kharasch ED. Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology 2008; 108(3): 363-374.
19. Trkulja S and Kovar KA. Defi nite peak identifi cation of (R)-and (S)-methadone and (R)- and (S)-EDDP using established HPLC and CE methods. Journal of Separation Science 2004; 27(7-8): 557-559.
20. Wang JS and DeVane CL. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro. Drug Metabolism and Disposition: The Biological Fate of Chemicals 2003; 31(6): 742-747.
21. Wang JS, Ruan Y, Taylor RM, Donovan JL, Markowitz JS and DeVane CL. Brain penetration of methadone (R)- and (S)-enantiomers is greatly increased by P-glycoprotein defi ciency in the blood-brain barrier of Abcb1a gene knockout mice. Psychopharmacology (Berlin) 2004; 173(1-2): 132-138.